TSRL, Inc. President and CEO Dr. Elke Lipka recently joined fellow business and community leaders to accept two honors recognizing her leadership and impact across Michigan. Dr. Lipka was named among Michigan’s Most Inspiring Leaders and received a Corp! Magazine MVP Award, adding to a growing list of recognition for the leadership team at TSRL and contributions to Michigan’s life sciences community.

TSRL, Inc. today announced that President and CEO Dr. Elke Lipka will be presenting at the PharmaEd Microneedle & Transdermal Delivery Forum 2026, one of the leading conferences dedicated to skin-mediated therapies and advanced drug delivery technologies. The conference will be held August 27 and 28 in Providence, Rhode Island, bringing together researchers from industry, academia, and regulatory organizations to discuss the latest advances in microneedle and transdermal drug delivery.

TSRL, Inc. today announced that it has received its second-year Notice of Award from the National Institutes of Health (NIH) to continue advancing its microneedle patch for the treatment of overactive bladder. The award, issued last month, provides nearly $1.1 million in continued support under Grant Number 5R44DK143799-03.

TSRL recently hosted a group of students at our Ann Arbor headquarters for a behind-the-scenes look at preclinical drug development. The visit gave students the opportunity to learn about our scientific work, connect with our team, and explore careers across the drug development process.

Drug development is becoming more integrated, strategic, and collaborative. Learn what TSRL President and CEO Dr. Elke Lipka took away from the MichBio 2026 Drug Discovery and Development Symposium.

TSRL has expanded its scientific advisory team with the addition of Lisa Crandall as Senior Scientific Advisor. With more than 25 years of pharmaceutical experience spanning CMC strategy, formulation, analytical development, and regulatory affairs, Crandall brings deep expertise to support clients navigating complex drug development programs.

As a part of our series, we had the pleasure to interview Elke Lipka.

Dr. Elke Lipka is the President and Chief Executive Officer of TSRL, Inc., having been with the company for more than 20 years, and she was recognized as one of the “Top Women in Tech to Know in 2026” by Purpose Jobs. Under her leadership, TSRL has built a reputation becoming the preclinical CRO of choice by strategically moving complex drug candidates toward the clinic. Dr. Lipka has secured nearly $20 million in non-dilutive funding to advance TSRL’s portfolio and expand partnerships with academic, government, and industry innovators across the United States and Europe.

TSRL, Inc. today announced its contribution to a newly published study in Microbiology Spectrum by the American Society of Microbiology (ASM) evaluating the in vitro activity of MRS-2541, a novel methionyl-tRNA synthetase inhibitor designed to target serious gram-positive hospital infections.

The Michigan Mass Spectrometry Discussion Group Symposium, held March 18, 2026 at the Van Andel Institute in Grand Rapids, brought together experts across academia and industry to discuss advances, challenges, and future directions in mass spectrometry. TSRL’s John Takyi-Williams, PhD, Senior Research and Project Scientist, Analytical, attended and shared key observations.

TSRL, Inc. President and CEO Dr. Elke Lipka and Senior Advisor Dr. Jessica Reed have been named to Purpose Jobs’ “43 Top Women in Tech to Know in 2026” list, recognizing leaders who are driving meaningful innovation across technology and science.

The Preclinical Contract Research Organization (CRO) market is growing and expected to eclipse USD 11.3 billion by 2033, according to Research and Markets in Yahoo! Finance. With thousands of preclinical CROs in the US alone, selecting the right preclinical CRO becomes one of your most important decisions.

In an industry where few independent preclinical CROs last more than a decade, TSRL’s 40-year milestone is a rare achievement. Founded in 1986 in Ann Arbor, Michigan with a vision to improve drug delivery for small molecules, the company has evolved into a science-first CRO known for its keen sense of strategy, high data quality, and lasting relationships across academia and industry.

TSRL, Inc. announced that it has received a new $2.2 million grant award from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH) under Award Number R44DK143799, to advance the development of a weekly microneedle patch for the treatment of overactive bladder (OAB).

TSRL, Inc. announced today the appointment of Gerry Cox to its Board of Directors, effective immediately. Cox brings more than 30 years of biopharma leadership experience in pharmaceuticals and life sciences, having held senior executive positions at major industry players including Pfizer, Velesco, and Pace Analytical Life Sciences.

Three Michigan-based companies—TSRL Inc., AnchorBio, and AAPharmaSyn—have announced the formation of The A2 BioPharm Collaborative, a new strategic collaboration aimed at accelerating drug development from target identification to IND-enabling studies.

TSRL is excited to announce our sponsorship of the A2 BioSocial – June Celebration, taking place on Tuesday, June 3, 2025, from 5:00 to 7:30 PM at the vibrant HOMES Campus – Beer Garden in Ann Arbor, MI.

We are excited to share that our CEO, Dr. Elke Lipka, will be attending BIO International Convention 2025 in our kiosk as part of the Michigan Pavilion!

TSRL, Inc. announced today that the company was awarded a Phase IIB Small Business Technology Transfer (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH).

TSRL, Inc. announced that in September the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH).

TSRL, Inc., a privately-held preclinical accelerator, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health (NIH) for about $300,000 over 12 months.

TSRL, Inc. will continue to broaden its MAP portfolio with the development of a once-a-week patch of Trospium Chloride (TC) optimized for improved tolerance and patient outcomes in overactive bladder (OB) disease.